Development of a ZHER3-Affibody-Targeted Nano-Vector for Gene Delivery to HER3-Overexpressed Breast Cancer Cells.
Mahboobeh NazariSaeideh Zamani KoukhalooSamira MousaviArash Minai-TehraniRahman EmamzadehRoya CheraghiPublished in: Macromolecular bioscience (2019)
Despite the initial successes of gene delivery applications, they faced on several intrinsic drawbacks including toxicity and immunogenicity. Therefore, alternative gene-delivery systems derived from recombinant peptides have emerged and is rapidly developing. Human epidermal growth factor receptor-3 (HER3) shows high activity in tumor resistance to anti-human epidermal growth factor receptor 2 (HER2) therapies. In this study, an affibody molecule against HER3 is conjugated to a biomimetic peptide RALA (an amphipathic and cationic peptide enriched with arginine) and the ability of the fusion vector for targeting HER3 and afterward delivering specific genes in breast cancer cells is evaluated. The results demonstrate that the biopolymeric platform, which contains an affibody-conjugated RALA peptide, can effectively condense DNA into nanoparticles and target the overexpressed HER3 receptors in breast cancer cells and transfer specific genes. The use of such a recombinant biopolymer may pave the way for the development of sensitive and effective diagnostic and treatment tool for breast cancer.
Keyphrases
- epidermal growth factor receptor
- breast cancer cells
- tyrosine kinase
- advanced non small cell lung cancer
- endothelial cells
- genome wide
- genome wide identification
- induced pluripotent stem cells
- cell free
- photodynamic therapy
- nitric oxide
- copy number
- genome wide analysis
- oxidative stress
- single molecule
- high throughput
- dna methylation
- gene expression
- circulating tumor
- bioinformatics analysis
- drug delivery
- single cell
- smoking cessation
- replacement therapy
- circulating tumor cells